Gene Expression Profiling of Peripheral Blood Leukocytes Shows Consistent Longitudinal Downregulation of TOMM40 and Upregulation of KIR2DL5A, PLOD1, and SLC2A8 Among Fast Progressors in Early Alzheimer's Disease

2013 ◽  
Vol 34 (2) ◽  
pp. 399-405 ◽  
Author(s):  
Mei Sian Chong ◽  
Liang Kee Goh ◽  
Wee Shiong Lim ◽  
Mark Chan ◽  
Laura Tay ◽  
...  
2005 ◽  
Vol 52 (3,4) ◽  
pp. 137-144 ◽  
Author(s):  
Kazuhito Rokutan ◽  
Kyoko Morita ◽  
Kiyoshi Masuda ◽  
Kumiko Tominaga ◽  
Michiyo Shikishima ◽  
...  

Author(s):  
H.-T. Li ◽  
S.-X. Yuan ◽  
J.-S. Wu ◽  
X.-Z. Zhang ◽  
Y. Liu ◽  
...  

Background: Alzheimer’s Disease (AD) is a neurodegenerative brain disease in the elderly. Recent studies have revealed the heterogeneous nature of AD. Mild Cognitive Impairment (MCI) is the prodromal stage of AD. Objectives: In this study, we identified subtypes of MCI based on genetic polymorphism and gene expression. Methods: We utilized the two types of omics data, namely genetic polymorphism and gene expression profiling, derived from 125 MCI patients’ peripheral blood samples from the ADNI-1 dataset. Similarity network fusion (SNF) algorithm was implemented to cluster MCI patient subtypes. And 185 MCI patients in ADNI-2 were utilized to evaluate the effectiveness of this method. Two MCI subtypes were identified by implementing the SNF algorithm. Results: We used Kaplan-Meier analysis and log-rank testing for the conversion from MCI to AD between two subtypes, and p-value is 4.58×10-3. In addition, we compared patients among two MCI subtypes by the following factors: the changes in Alzheimer’s Disease cognitive scales and MRI image; significantly enriched pathways based on differentially expressed genes. This study proved that MCI is a heterogeneous disease by concluding that AD development in two MCI subtypes is significantly different. Conclusions: MCI patients with different molecular characteristics have different risks converting to AD. In addition to evaluating statistics, genetic polymorphism and gene expression profiling from MCI patients’ peripheral blood are non-invasiveness and cost-effectiveness markers to identify MCI subtypes for clinical application.


2019 ◽  
Vol 137 (4) ◽  
pp. 557-569 ◽  
Author(s):  
Stephen A. Semick ◽  
Rahul A. Bharadwaj ◽  
Leonardo Collado-Torres ◽  
Ran Tao ◽  
Joo Heon Shin ◽  
...  

2014 ◽  
Vol 10 ◽  
pp. P216-P216
Author(s):  
Mariet Allen ◽  
Daniel Serie ◽  
Zhifu Sun ◽  
Saurabh Baheti ◽  
Mike Walsh ◽  
...  

2008 ◽  
Vol 4 ◽  
pp. T759-T759
Author(s):  
Sandra Pereson ◽  
Mado Vandewoestyne ◽  
Bianca Van Broeck ◽  
Ivy Cuijt ◽  
Edith Peeters ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document